Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54:367–376. https://doi.org/10.1007/s00535-018-1532-5

Article  CAS  PubMed  Google Scholar 

Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. 2024;54:763–772. https://doi.org/10.1111/hepr.14047

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694–701. https://doi.org/10.1016/j.jhep.2024.01.014

Article  CAS  PubMed  Google Scholar 

Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T. Changing from NAFLD to MASLD: similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD. Clin Mol Hepatol. 2024;30:263–265. https://doi.org/10.3350/cmh.2023.0557

Article  PubMed  PubMed Central  Google Scholar 

Meyer M, Schwärzler J, Jukic A, Tilg H. Innate immunity and MASLD. Biomolecules. 2024;14:476. https://doi.org/10.3390/biom14040476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D, et al. Activated natural killer cell promotes non-alcoholic steatohepatitis through mediating JAK/STAT pathway. Cell Mol Gastroenterol Hepatol. 2022;13:257–274. https://doi.org/10.1016/j.jcmgh.2021.08.019

Article  CAS  PubMed  Google Scholar 

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology. 2010;51:92–102. https://doi.org/10.1002/hep.23253

Article  CAS  PubMed  Google Scholar 

Kahraman A, Fingas CD, Syn WK, Gerken G, Canbay A. Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 2012;32:370–382. https://doi.org/10.1111/j.1478-3231.2011.02608.x

Article  CAS  PubMed  Google Scholar 

Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455–458. https://doi.org/10.1038/ng.809

Article  CAS  PubMed  Google Scholar 

Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 1996;93:12445–12450. https://doi.org/10.1073/pnas.93.22.12445

Article  CAS  PubMed  PubMed Central  Google Scholar 

Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85–100. https://doi.org/10.1038/s41571-020-0426-7

Article  PubMed  Google Scholar 

Arai J, Okumura A, Kato N, Ito K. Natural killer group 2D-major histocompatibility complex class I polypeptide-related sequence A activation enhances natural killer cell-mediated immunity against hepatocellular carcinoma: a review. Hepatol Res. 2024;54:420–428. https://doi.org/10.1111/hepr.14038

Article  CAS  PubMed  Google Scholar 

Chen L, Feng J, Xu B, Zhou Y, Zheng X, Wu C, et al. B7–H6 expression in human hepatocellular carcinoma and its clinical significance [corrected]. Cancer Cell Int. 2018;18:126. https://doi.org/10.1186/s12935-018-0627-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiyoaki I, Sumida Y, Nakade Y, Okumura A, Nishimura S, Ibusuki M, et al. Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis. PLoS ONE. 2022;17: e0277380. https://doi.org/10.1371/journal.pone.0277380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. https://doi.org/10.1097/HEP.0000000000000520

Article  PubMed  Google Scholar 

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. https://doi.org/10.1016/s0016-5085(99)70506-8

Article  CAS  PubMed  Google Scholar 

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. https://doi.org/10.1002/hep.20701

Article  PubMed  Google Scholar 

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325. https://doi.org/10.1002/hep.21178

Article  CAS  PubMed  Google Scholar 

Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. https://doi.org/10.1038/srep01065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arai J, Goto K, Stephanou A, Tanoue Y, Ito S, Muroyama R, et al. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2018;33:1075–1081. https://doi.org/10.1111/jgh.14029

Article  CAS  PubMed  Google Scholar 

Friedman SL. Hepatic fibrosis and cancer: the silent threats of metabolic syndrome. Diabetes Metab J. 2024;48:161–169. https://doi.org/10.4093/dmj.2023.0240

Article  PubMed  PubMed Central  Google Scholar 

Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2023;21:370–379. https://doi.org/10.1016/j.cgh.2022.01.002

Article  CAS  PubMed  Google Scholar 

Sawada K, Chung H, Softic S, Moreno-Fernandez ME, Divanovic S. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2023;35:1852–1871. https://doi.org/10.1016/j.cmet.2023.10.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marinović S, Lenartić M, Mladenić K, Šestan M, Kavazović I, Benić A, et al. NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis. Sci Immunol. 2023;8:eadd1599. https://doi.org/10.1126/sciimmunol.add1599

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261–272. https://doi.org/10.1007/s00535-014-1000-9

Article  CAS  PubMed  Google Scholar 

Arai J, Otoyama Y, Nozawa H, Kato N, Yoshida H. The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review. Oncogene. 2023;42:549–558. https://doi.org/10.1038/s41388-022-02583-5

Article  CAS  PubMed  Google Scholar 

Nishikawa M, Kinoshita M, Morimoto Y, Ishikiriyama T, Nakashima M, Nakashima H, et al. Lipopolysaccharide preconditioning reduces liver metastasis of colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver. J Gastroenterol Hepatol. 2021;36:1889–1898. https://doi.org/10.1111/jgh.15375

Article